Clearbridge Health reported FY 2025 revenue of SGD 9.929 million (up 0.3%) and a total loss of SGD 13.072 million (up 213.7%) for the year ended 31 December 2025, reflecting an impairment loss on goodwill of SGD 8.589 million and a fair value loss on derivative financial instruments of SGD 0.917 million. Loss attributable to shareholders from continuing operations was SGD 12.908 million in FY 2025, with basic and diluted loss per share from continuing operations of 0.39 Singapore cents. For H2 2025, revenue was SGD 5.014 million (down 6.4%) and total loss was SGD 11.498 million (up 800.4%), including the same SGD 8.589 million goodwill impairment and a SGD 0.863 million fair value loss on derivative financial instruments. Net cash used in operating activities was SGD 2.656 million in FY 2025, and cash and cash equivalents were SGD 0.990 million at 31 December 2025. Net asset value per share was 0.08 Singapore cents at 31 December 2025 (from 0.50 Singapore cents). Corporate and business updates during FY 2025 included the full conversion of the company’s outstanding convertible bonds on 2 May 2025, and the issuance of 990,000,000 placement shares on 18 August 2025 alongside 659,999,996 non-listed warrants with an exercise price of SGD 0.0024 per share. The group also started a cell banking business in H2 2025, reporting SGD 0.004 million of revenue in FY 2025, and incorporated a wholly-owned Hong Kong subsidiary, Cell Entrust Bio Co. Limited, on 9 July 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearbridge Health Ltd. published the original content used to generate this news brief via Singapore Exchange Limited (SGX) (Ref. ID: LQ3O9PTV712ZYIZA) on February 27, 2026, and is solely responsible for the information contained therein.